CD38 and neoplasm: Interestingly, combination treatment with guadecitabine/ICBs determined a significant increase of M1 (CD38+Egr2-) macrophages, respect to control and ICBs, indicating that triple therapy skews towards pro inflammatory anti-tumor TAM-M1 responses (Fig. 4B).